Dravet Syndrome Treatment Market Size & Share, by Seizures Type (Absence Seizures, Tonic Seizures, Photosensitive Seizures, Myoclonic Seizures, Atonic Seizures, Partial Seizures); Diagnosis Type (Magnetic Resonance Imaging, Electroencephalography, SCN1 A Testing); Treatment Type (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation); Product (SDGs, TGDs, FGDs); End-user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5280
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Dravet Syndrome Treatment Market size is poised to reach USD 1 Billion by the end of 2036, growing at a CAGR of 11% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of dravet syndrome treatment was USD 0.37 Billion. The reason behind the growth is impelled by the increasing child population. Moreover, Dravet syndrome is an uncommon kind of epilepsy that starts in infancy or early childhood and can lead to frequent, protracted seizures, which may require treatment including medication or other therapies to decrease the severity and amount of seizures.According to estimates, the number of children worldwide is projected to be over 1 billion in 2100.

The growing research & development are believed to fuel the dravet syndrome treatment market. For instance, in 2020 STK-001 an anti-sense oligonucleotide was administered, to the first patient with Dravet syndrome as part of a clinical trial to increase the expression of SCN1A in the brain.

/admin/upload_images/Dravet Syndrome Treatment Market.webp
Get more information on this report: Request Free Sample PDF

Dravet Syndrome Treatment Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 0.37 Billion

Forecast Year Market Size (2036)

~ USD 1 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Dravet Syndrome Treatment Market: Growth Drivers and Challenges


Growth Drivers

  • Rising Drug Development – The FDA may collaborate with businesses to develop medications for Dravet syndrome, which is expected to drive market growth. According to recent estimates, the typical R&D expenditure for a new medicine ranges from more than USD 1 billion.
  • Growing Importance of Genetic Testing- Genetic testing is a straightforward blood test that can reveal sequencing abnormalities in the SCN1A gene that can help in determining whether an individual has Dravet syndrome by analyzing the most prevalent genes linked to epilepsy.


  • High Cost of Treatments - Dravet syndrome is a rare disease that affects a small percentage of people, therefore the medicines for treating this disease are exceedingly expensive, presumably to cover the cost of the research and development.  For instance, more than a 20% rise in overall expenses is linked to the absence of treatment for a rare condition.
  • Complexity Associated With Meeting Regulatory Requirements for the Approval of Rare Disease Treatment
  • Lack of Awareness among Doctors and Patients Owing to Rarity of Dravet Syndrome

Dravet Syndrome Treatment Segmentation

Product (SGDs, TGDs, FGDs)

The SGDs segment is estimated to account for 45% share of the dravet syndrome treatment market in the coming years. The only SGDs that are currently available for the treatment of DS are stiripentol and topiramate out of which the only medication that has been proven to adequately treat Dravet-related seizures is stiripentol which is available in the form of hard capsules or a powder for oral suspension. Besides this, it can be used as an orphan medication in the supplementary management of childhood epilepsy syndrome.

End-User (Pharmaceutical Companies, Hospital Pharmacies, Diagnostic Laboratories, Academic and Research Institutes)

Dravet syndrome treatment market from the hospital pharmacies segment is set to garner a notable share shortly. Drugs, such as valproate, clobazam, stiripentol, cannabidiol, or fenfluramine, are used to treat patients with Dravet syndrome which are provided by hospital pharmacies as it has the required skills for pricing, dispensing, and the availability of skilled hospital pharmacists to manage these medications.

Treatment Type (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation)

The seizure medications segment in the dravet syndrome treatment market is set to garner a significant share during the forecast timeframe. Seizure medications work to halt or prevent seizures by functioning in a variety of ways. For instance, more than 60% of epilepsy sufferers can control their seizures with medication. Moreover, anti-seizure drugs function by lessening the aberrant electrical activity in the brain and help in managing the type of pain brought on by damaged nerves.

Diagnosis Type (Magnetic Resonance Imaging, Electroencephalography, SCN1 A Testing)

The magnetic resonance imaging segment in the dravet syndrome treatment market is set to garner a significant share by the year 2036. Dravet syndrome (DS) and other neurological conditions may be distinguished using (MRI) since it creates extremely accurate images of a child's brain using a magnetic field and radio waves.

Our in-depth analysis of the global market includes the following segments:

          Seizures Type

  • Absence Seizures
  •  Tonic Seizures
  •  Photosensitive Seizures
  • Myoclonic Seizure
  •  Atonic Seizures
  • Partial Seizures

          Diagnosis Type

  • Magnetic Resonance Imaging
  • Electroencephalography
  •  SCN1 A Testing


  • Pharmaceutical Companies
  • Hospital Pharmacies
  • Diagnostic Laboratories
  • Academic and Research Institutes

          Treatment Type

  • Seizure Medications
  • Ketogenic Diet
  •  Vagus Nerve Stimulation


  • SDGs
  •  TGDs
  • FGDs

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Dravet Syndrome Treatment Industry- Regional Synopsis

North American Market Forecast

Dravet syndrome treatment market in North America is predicted to account for the largest share of 39% by 2036 impelled by the rising spending in healthcare. This has led to an increase in research & development of more efficient and effective treatments for Dravet syndrome in the region, which would also improve access to the treatment of the disease in the region. According to estimates, in 2021, the United States spent over 2% more on health care, amounting to roughly USD 4 trillion.

European Market Statistics

The Europe dravet syndrome Treatment market is estimated to be the second largest, during the forecast timeframe led by growing development of new drugs. For instance, Europe serves as the world's center for medication development, as over 72 novel opioids have been discovered on the European drug market between 2009 and 2022. This has led to an expansion in treatment options for Dravet syndrome in the region.  

Research Nester
/admin/upload_images/Dravet Syndrome Treatment Market  Size.webp
Get more information on this report: Request Free Sample PDF

Companies Dominating the Dravet Syndrome Treatment Landscape

    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cadila Healthcare Ltd.
    • Encoded Therapeutics Inc.
    • Epygenix Therapeutics Inc.
    • H Lundbeck AS
    • Jazz Pharmaceuticals Plc
    • Johnson and Johnson
    • Lupin Ltd.
    • PTC Therapeutics Inc.
    • Stoke Therapeutics Inc.
    • Supernus Pharmaceuticals Inc.
    • Sun Pharmaceutical Industries Ltd.


In The News

  • Cadila Healthcare Ltd. an innovative, global pharmaceutical company received approval from the USFDA for a seizure treatment drug, vigabatrin tablets in the strength of 500 mg, which is capable of reducing the frequency of seizures in both adults and kids who haven't been able to manage their seizures with existing treatments by preventing the breakdown of GABA, a naturally occurring tranquilizer, in the brain.
  • Encoded Therapeutics Inc. received over USD 130 million to fund the initial human clinical studies of ETX101, which was given classifications as an orphan drug and a rare pediatric condition by the American Food and Drug Administration (FDA). Furthermore, ETX101 was created to raise NaV1.1-alpha levels to prepare it for the clinic and beyond, and to attract some of the most knowledgeable senior leaders in gene therapy.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5280
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing child population and the growing research & development are the major factors driving the growth of the market.

The market size of Dravet Syndrome Treatment is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.

The SGDs segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Dravet Syndrome Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying